Efficacy of antifungal therapy in a nonneutropenic murine model of zygomycosis.
Three isolates of zygomycetes belonging to three different genera (Rhizopus microsporus, Absidia corymbifera, and Apophysomyces elegans) were used to produce a disseminated infection in nonimmunocompromised mice. The therapeutic efficacy of amphotericin B, given intraperitoneally at doses ranging from 0.5 to 4.5 mg/kg of body weight/day, oral itraconazole at 100 mg/kg/day, and oral terbinafine at 150 mg/kg/day was evaluated in this model. The markers of antifungal efficacy were the median survival time, the mortality rate, and the percentage of infected organs. Organ culture was performed along with microscopic direct examinations of tissues to assess the presence of an active infection. An acute and lethal infection was obtained in untreated mice challenged with each of the three strains. The data obtained for direct examinations and qualitative cultures indicate that, due to the nonseptate nature of the hyphae, each technique gives different information and should be used together with the others. Against all three strains, amphotericin B yielded a 90 to 100% survival rate. Itraconazole was inactive against R. microsporus but significantly reduced mortality in mice infected with A. corymbifera or A. elegans. Terbinafine had no beneficial effects against R. microsporus and A. corymbifera despite documented absorption of the drug. Overall, only limited correlations were observed between MICs determined in vitro and in vivo efficacy of the drugs. The efficacy of itraconazole in these models of zygomycosis suggests that this drug, as well as the new azole compounds presently under development, warrants close evaluation.
Dannaoui
Eric
E
Department of Medical Microbiology, University Medical Center St. Radboud, 6500 HB Nijmegen, The Netherlands.
Mouton
Johan W
JW
Meis
Jacques F G M
JF
Verweij
Paul E
PE
D020095:Absidia / Q000187:drug effects; D000666:Amphotericin B / Q000627:therapeutic use; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D001921:Brain / Q000382:microbiology; D005260:Female; D017964:Itraconazole / Q000627:therapeutic use; D007668:Kidney / Q000382:microbiology; D051379:Mice; D008826:Microbial Sensitivity Tests; D009090:Mucorales / Q000187:drug effects; D009281:Naphthalenes / Q000627:therapeutic use; D012233:Rhizopus / Q000187:drug effects; D016019:Survival Analysis; D000077291:Terbinafine; D020096:Zygomycosis / Q000188:drug therapy* / Q000382:microbiology* / Q000401:mortality
D000935:Antifungal Agents; D009281:Naphthalenes; D017964:Itraconazole; D000666:Amphotericin B; D000077291:Terbinafine